© 2000 The Royal College of Psychiatrists
Psychometric properties of the Social Phobia Inventory (SPIN)
New self-rating scale
Department of Psychiatry and Behavioral Sciences, Duke University, Medical Center, Durham, NC
University of Pennsylvania
Declaration of interest Supported in part by Social Phobia Grant IR10-MH49339 to J.R.T.D. and by a grant from Smith Kline Beecham.
Correspondence: Kathryn M. Connor, MD, Box 3812, Duke University Medical Center, Durham, NC 27710, USA. Tel: (919) 684-5849; Fax: (919) 684-8866; e-mail: kathryn.connor{at}duke.edu
Background Of available self-rated social phobia scales, none assesses the spectrum of fear, avoidance, and physiological symptoms, all of which are clinically important. Because of this limitation, we developed the Social Phobia Inventory (SPIN).
Aims To establish psychometric validation of the SPIN.
Method Subjects from three clinical trials and two control groups were given the 17-item, self-rated SPIN. Validity was assessed against several established measures of social anxiety, global assessments of severity and improvement, and scales assessing physical health and disability.
Results Good test—retest reliability, internal consistency, convergent and divergent validity were obtained. A SPIN score of 19 distinguished between social phobia subjects and controls. The SPIN was responsive to change in symptoms over time and reflected different responses to active drugs v. placebo. Factorial analysis identified five factors.
Conclusions The SPIN demonstrates solid psychometric properties and shows promise as a measurement for the screening of, and treatment response to, social phobia.
This article has been cited by other articles:
 |
|
 |
|
  K Poder, K Ghatavi, J. Fisk, T. Campbell, S Kisely, I Sarty, K Stadnyk, and V Bhan Social anxiety in a multiple sclerosis clinic population Multiple Sclerosis, March 1, 2009; 15(3): 393 - 398. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Katerelos, L. L. Hawley, M. M. Antony, and R. E. McCabe The Exposure Hierarchy as a Measure of Progress and Efficacy in the Treatment of Social Anxiety Disorder Behav Modif, July 1, 2008; 32(4): 504 - 518. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Sprafkin, K. D. Gadow, M. D. Weiss, J. Schneider, and E. E. Nolan Psychiatric Comorbidity in ADHD Symptom Subtypes in Clinic and Community Adults J Atten Disord, September 1, 2007; 11(2): 114 - 124. [Abstract] [PDF]
|
|
|
|
 |
|
 R. P Swinson The GAD-7 scale was accurate for diagnosing generalised anxiety disorder Evid. Based Med., December 1, 2006; 11(6): 184 - 184. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zhang, K. M. Connor, and J. R. T. Davidson Levetiracetam in social phobia: a placebo controlled pilot study J Psychopharmacol, September 1, 2005; 19(5): 551 - 553. [Abstract] [PDF]
|
|
|
|
 |
|
 M. R. Liebowitz, A. J. Gelenberg, and D. Munjack Venlafaxine Extended Release vs Placebo and Paroxetine in Social Anxiety Disorder Arch Gen Psychiatry, February 1, 2005; 62(2): 190 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Veale Treatment of social phobia Adv. Psychiatr. Treat., July 1, 2003; 9(4): 258 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Stein, M. Versiani, T. Hair, and R. Kumar Efficacy of Paroxetine for Relapse Prevention in Social Anxiety Disorder: A 24-Week Study Arch Gen Psychiatry, December 1, 2002; 59(12): 1111 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Katzelnick, K. A. Kobak, T. DeLeire, H. J. Henk, J. H. Greist, J. R.T. Davidson, F. R. Schneier, M. B. Stein, and C. P. Helstad Impact of Generalized Social Anxiety Disorder in Managed Care Am J Psychiatry, December 1, 2001; 158(12): 1999 - 2007. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Stein, J. Sareen, S. Hami, and J. Chao Pindolol Potentiation of Paroxetine for Generalized Social Phobia: A Double-Blind, Placebo-Controlled, Crossover Study Am J Psychiatry, October 1, 2001; 158(10): 1725 - 1727. [Abstract] [Full Text] [PDF]
|
|